EA201500575A1 - Транс-4-{2-[4-(2,3-дихлорфенил)пиперазин-1-ил]этил}-n,n-диметилкарбамоилциклогексиламин для лечения негативных симптомов шизофрении - Google Patents

Транс-4-{2-[4-(2,3-дихлорфенил)пиперазин-1-ил]этил}-n,n-диметилкарбамоилциклогексиламин для лечения негативных симптомов шизофрении

Info

Publication number
EA201500575A1
EA201500575A1 EA201500575A EA201500575A EA201500575A1 EA 201500575 A1 EA201500575 A1 EA 201500575A1 EA 201500575 A EA201500575 A EA 201500575A EA 201500575 A EA201500575 A EA 201500575A EA 201500575 A1 EA201500575 A1 EA 201500575A1
Authority
EA
Eurasian Patent Office
Prior art keywords
negative symptoms
piperazin
trans
ethyl
treatment
Prior art date
Application number
EA201500575A
Other languages
English (en)
Other versions
EA039245B1 (ru
Inventor
Янош Дьёрдь Питтер
Балаж Сатмари
Марк Дебелль
Дьёрдь Йожеф Немет
Иштван Ласловски
Original Assignee
Рихтер Гедеон Нирт.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рихтер Гедеон Нирт. filed Critical Рихтер Гедеон Нирт.
Publication of EA201500575A1 publication Critical patent/EA201500575A1/ru
Publication of EA039245B1 publication Critical patent/EA039245B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Abstract

Настоящее изобретение имеет отношение к транс-4-{2-[4-(2,3-дихлорфенил)пиперазин-1-ил]этил}-N,N-диметилкарбамоилциклогексиламину (карипразину) и его фармацевтически приемлемым солям, гидратам, сольватам и полиморфным формам для использования при лечении первичных негативных симптомов шизофрении и/или преимущественно негативных симптомов шизофрении.
EA201500575A 2012-11-29 2013-11-28 Транс-4-{2-[4-(2,3-дихлорфенил)пиперазин-1-ил]этил}-n,n-диметилкарбамоил-циклогексиламин для лечения негативных симптомов шизофрении EA039245B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1200691A HU231227B1 (hu) 2012-11-29 2012-11-29 Transz-4-{2-[4-(2,3-diklórfenil)-piperazin-1-il]-etil}N,N-dimetilkarbamoil-ciklohexilamin skizofrénia negatív tüneteinek kezelésére
PCT/IB2013/060465 WO2014083522A1 (en) 2012-11-29 2013-11-28 Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-n,n-dimethylcarbamoyl-cyclohexylamine for treating negative symptoms of schizophrenia

Publications (2)

Publication Number Publication Date
EA201500575A1 true EA201500575A1 (ru) 2015-09-30
EA039245B1 EA039245B1 (ru) 2021-12-22

Family

ID=70289034

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201500575A EA039245B1 (ru) 2012-11-29 2013-11-28 Транс-4-{2-[4-(2,3-дихлорфенил)пиперазин-1-ил]этил}-n,n-диметилкарбамоил-циклогексиламин для лечения негативных симптомов шизофрении

Country Status (36)

Country Link
US (1) US20150306094A1 (ru)
EP (2) EP3653211A1 (ru)
JP (2) JP2016501215A (ru)
KR (2) KR20210010955A (ru)
CN (1) CN104812390A (ru)
AP (1) AP2015008448A0 (ru)
AU (1) AU2013350819B9 (ru)
BR (1) BR112015012512A2 (ru)
CA (1) CA2890952A1 (ru)
CL (1) CL2015001468A1 (ru)
CR (1) CR20150244A (ru)
CY (1) CY1123766T1 (ru)
DK (1) DK2925324T3 (ru)
EA (1) EA039245B1 (ru)
ES (1) ES2863052T3 (ru)
GE (1) GEP20186849B (ru)
HK (1) HK1212608A1 (ru)
HR (1) HRP20210486T1 (ru)
HU (2) HU231227B1 (ru)
IL (1) IL238723B (ru)
LT (1) LT2925324T (ru)
MD (2) MD4865C1 (ru)
MX (2) MX2015006677A (ru)
MY (1) MY174663A (ru)
NI (1) NI201500074A (ru)
NZ (1) NZ708295A (ru)
PE (1) PE20151052A1 (ru)
PH (1) PH12015501124B1 (ru)
PL (1) PL2925324T3 (ru)
PT (1) PT2925324T (ru)
RS (1) RS61509B1 (ru)
SG (1) SG11201503672SA (ru)
SI (1) SI2925324T1 (ru)
UA (1) UA123492C2 (ru)
WO (1) WO2014083522A1 (ru)
ZA (1) ZA201503660B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2975A (en) 2008-07-16 2014-09-30 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands
CN105218484B (zh) * 2015-09-14 2018-02-23 安徽省逸欣铭医药科技有限公司 酒石酸卡利拉嗪及其制备方法和医药用途
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
HU231173B1 (hu) * 2016-07-08 2021-06-28 Richter Gedeon Nyrt. Ipari eljárás cariprazine előállítására
WO2019016828A1 (en) * 2017-07-15 2019-01-24 Msn Laboratories Private Limited, R&D Center NOVEL PROCESSES FOR THE PREPARATION OF TRANS-N- {4- [2- [4- (2,3-DICHLOROPHENYL) PIPERAZIN-1-YL] ETHYL] CYCLOHEXYL} -N ', N'-DIMETHYLUMED HYDROCHLORIDE AND POLYMORPHS THIS ONE
US20200375983A1 (en) * 2017-12-01 2020-12-03 Aurobindo Pharma Ltd A process for the preparation of cariprazine hydrochloride
WO2020056929A1 (zh) * 2018-09-21 2020-03-26 上海诚妙医药科技有限公司 卡利拉嗪盐酸盐的新晶型及其制备方法及其用途
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
US11344503B2 (en) 2019-12-13 2022-05-31 Halo Science LLC Cariprazine release formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227534B1 (en) 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
HU230748B1 (hu) 2007-05-11 2018-02-28 Richter Gedeon Nyrt Új piperazin só és előállítási eljárása
KR20100022955A (ko) * 2007-05-24 2010-03-03 리히터 게데온 닐트. (티오) -카르바모일-시클로헥산 유도체 및 정신분열 치료 방법
HUP0700369A2 (en) 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment in the manufacture of a medicament for the treatment of schizophrenia
WO2010126527A1 (en) * 2009-05-01 2010-11-04 Forest Laboratories Holdings Limited Methods of treating cns disorders

Also Published As

Publication number Publication date
CY1123766T1 (el) 2022-05-27
IL238723B (en) 2020-02-27
MY174663A (en) 2020-05-05
CR20150244A (es) 2015-06-23
LT2925324T (lt) 2021-02-25
JP2016501215A (ja) 2016-01-18
MD20150058A2 (ru) 2015-11-30
UA123492C2 (uk) 2021-04-14
KR102314248B1 (ko) 2021-10-19
MX2015006677A (es) 2015-08-10
EA039245B1 (ru) 2021-12-22
RS61509B1 (sr) 2021-03-31
KR20210010955A (ko) 2021-01-28
NI201500074A (es) 2015-09-18
AU2013350819B9 (en) 2018-06-21
AP2015008448A0 (en) 2015-05-31
MD20200089A2 (ru) 2021-05-31
EP2925324B1 (en) 2020-12-30
CN104812390A (zh) 2015-07-29
JP2019163240A (ja) 2019-09-26
BR112015012512A2 (pt) 2017-07-11
WO2014083522A1 (en) 2014-06-05
IL238723A0 (en) 2015-06-30
HUP1200691A1 (ru) 2014-06-30
MD4865C1 (ru) 2024-02-29
AU2013350819A1 (en) 2015-06-04
PE20151052A1 (es) 2015-08-09
SG11201503672SA (en) 2015-06-29
NZ708295A (en) 2020-03-27
MD4865B1 (ru) 2023-07-31
AU2013350819B2 (en) 2018-05-31
PL2925324T3 (pl) 2021-06-28
PT2925324T (pt) 2021-02-16
KR20150088270A (ko) 2015-07-31
ZA201503660B (en) 2016-03-30
SI2925324T1 (sl) 2021-04-30
HU231227B1 (hu) 2022-03-28
DK2925324T3 (da) 2021-03-01
EP2925324A1 (en) 2015-10-07
US20150306094A1 (en) 2015-10-29
HRP20210486T1 (hr) 2021-05-14
PH12015501124A1 (en) 2015-08-03
CA2890952A1 (en) 2014-06-05
PH12015501124B1 (en) 2015-08-03
EP3653211A1 (en) 2020-05-20
CL2015001468A1 (es) 2015-08-07
MX2021000342A (es) 2021-04-13
ES2863052T3 (es) 2021-10-08
HUE054054T2 (hu) 2021-08-30
GEP20186849B (en) 2018-05-10
HK1212608A1 (zh) 2016-06-17

Similar Documents

Publication Publication Date Title
EA201500575A1 (ru) Транс-4-{2-[4-(2,3-дихлорфенил)пиперазин-1-ил]этил}-n,n-диметилкарбамоилциклогексиламин для лечения негативных симптомов шизофрении
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
CY1122272T1 (el) ΕΝΩΣΕΙΣ 3-ΚΥΚΛΟΕΞΕΝΥΛ ΚΑΙ ΚΥΚΛΟΕΞΥΛ ΥΠΟΚΑΤΕΣΤΗΜΕΝΟΥ ΙΝΔΟΛΙΟΥ ΚΑΙ ΙΝΔΑΖΟΛΙΟΥ ΩΣ RORgammaT ΑΝΑΣΤΟΛΕΙΣ ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
IN2015DN01156A (ru)
EA201690277A1 (ru) Производные замещенного глиоксамидом пирроламида и их применение в качестве лекарственных средств для лечения гепатита b
EA201490357A1 (ru) Индазолы
MA40171A (fr) Dérivés d'azamophinan et leur utilisation
EA201591195A1 (ru) Новые хинолоновые производные
MA40170A (fr) Dérivés hétérocycliques de morphinan et leur utilisation
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
EA201690888A1 (ru) Новые гетероциклические соединения
EA201600434A1 (ru) Применение производных бензимидазолпролина
CY1120133T1 (el) Πυριδαζινονες ως αναστολεις ενζυμου daao
AU2013369288A8 (en) Sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same
CY1118886T1 (el) Θεραπευτικες χρησεις της 1-[2-(2,4-διμεθυλ-φαινυλσουλφανυλ)φαινυλ]πιπεραζινης
EA201391793A1 (ru) Новый способ синтеза 7-хлор-4-(пиперазин-1-ил)-хинолина
EA201491878A1 (ru) Замещенные ксантиновые производные
EA201301235A1 (ru) Новый способ синтеза 3-(2-бром-4,5-диметоксифенил)пропаннитрила и применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
EA201301020A1 (ru) Новый способ синтеза 3-(2-бром-4,5-диметоксифенил)пропаннитрила и применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
EA201600032A1 (ru) Производные 1-сульфонилпиперидина в качестве модуляторов рецепторов прокинетицина
FR2977492B1 (fr) Nouvelle association entre le n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl) benzofuran-2-ylcarbonylamino]ethoxy}benzamide et le folfox